| OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer TY Seiwert, CC Foster, EA Blair, TG Karrison, N Agrawal, JM Melotek, ... Annals of Oncology 30 (2), 297-302, 2019 | 198 | 2019 |
| Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer VM Villaflor, JM Melotek, TG Karrison, RJ Brisson, EA Blair, L Portugal, ... Annals of Oncology 27 (5), 908-913, 2016 | 85 | 2016 |
| Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience CC Foster, JM Melotek, RJ Brisson, TY Seiwert, EEW Cohen, KM Stenson, ... Oral Oncology 80, 16-22, 2018 | 55 | 2018 |
| Immune‐related adverse events are associated with improved response, progression‐free survival, and overall survival for patients with head and neck cancer receiving immune … CC Foster, MA Couey, SE Kochanny, A Khattri, RK Acharya, YHC Tan, ... Cancer 127 (24), 4565-4573, 2021 | 34 | 2021 |
| Final results of a randomized phase 2 trial investigating the addition of cetuximab to induction chemotherapy and accelerated or hyperfractionated chemoradiation for … TY Seiwert, JM Melotek, EA Blair, KM Stenson, JK Salama, ME Witt, ... International Journal of Radiation Oncology* Biology* Physics 96 (1), 21-29, 2016 | 34 | 2016 |
| Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer S Shah, K Wood, B Labadie, B Won, R Brisson, T Karrison, T Hensing, ... Oncotarget 9 (4), 4375, 2018 | 30 | 2018 |
| Association of immune-related adverse events (irAEs) with improved response, progression-free survival, and overall survival for patients with metastatic head and neck cancer … CC Foster, S Kochanny, A Khattri, R Acharya, A Dekker, YHC Tan, ... Journal of Clinical Oncology 36 (15_suppl), 6014-6014, 2018 | 29 | 2018 |
| A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma SE Kochanny, FP Worden, DR Adkins, DW Lim, JE Bauman, SA Wagner, ... Cancer 126 (10), 2146-2152, 2020 | 28 | 2020 |
| Characterization of the T-cell receptor repertoire and immune microenvironment in patients with locoregionally advanced squamous cell carcinoma of the head and neck V Saloura, A Fatima, M Zewde, K Kiyotani, R Brisson, JH Park, Y Ikeda, ... Clinical Cancer Research 23 (16), 4897-4907, 2017 | 22 | 2017 |
| A pilot study of the pan‐class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer RJ Brisson, S Kochanny, S Arshad, A Dekker, JA DeSouza, V Saloura, ... Head & neck 41 (11), 3842-3849, 2019 | 20 | 2019 |
| Dose and volume de-escalation for human papillomavirus–positive oropharyngeal cancer is associated with favorable posttreatment functional outcomes CC Foster, TY Seiwert, E MacCracken, EA Blair, N Agrawal, JM Melotek, ... International Journal of Radiation Oncology* Biology* Physics 107 (4), 662-671, 2020 | 17 | 2020 |
| A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab‐resistant head and neck cancer: The MAESTRO study TY Seiwert, S Kochanny, K Wood, FP Worden, D Adkins, JL Wade, ... Cancer 126 (14), 3237-3243, 2020 | 13 | 2020 |
| The time course of semantic and relational processing during verbal analogical reasoning MJ Kmiecik, RJ Brisson, RG Morrison Brain and Cognition 129, 25-34, 2019 | 13 | 2019 |
| Association of a baseline neutrophil-to-lymphocyte ratio (NLR) with progression-free and overall survival in head and neck cancer patients receiving anti-PD-1 therapy. CC Foster, S Kochanny, A Khattri, R Acharya, A Dekker, YHC Tan, ... Journal of Clinical Oncology 36 (15_suppl), 6038-6038, 2018 | 10 | 2018 |
| 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one: National Harbor, MD, USA. 9-13 November 2016 A Lundqvist, V van Hoef, X Zhang, E Wennerberg, J Lorent, K Witt, ... Journal for immunotherapy of cancer 4, 1-106, 2016 | 10 | 2016 |
| The role of chemotherapy in the management of olfactory neuroblastoma: A 40‐year surveillance, epidemiology, and end results registry study RJ Brisson, TJ Quinn, RL Deraniyagala Health science reports 4 (2), e257, 2021 | 9 | 2021 |
| Optima: A phase II dose and volume de-escalation trial for high-and low-risk HPV+ oropharynx cancers. J Melotek, TY Seiwert, EA Blair, TG Karrison, N Agrawal, L Portugal, ... Journal of Clinical Oncology 35 (15_suppl), 6066-6066, 2017 | 9 | 2017 |
| The landscape of digital resources in radiation oncology MM Culbert, RJ Brisson, OT Oladeru Technical Innovations & Patient Support in Radiation Oncology 24, 19-24, 2022 | 7 | 2022 |
| Correlation of constitutive PD-1 resistance in HNC with GM-CSF expression and presence of myeloid derived suppressor cells (MDSCs). TY Seiwert, R Bao, YHC Tan, R Acharya, RJ Brisson, S Kochanny, ... Journal of Clinical Oncology 35 (15_suppl), 6049-6049, 2017 | 6 | 2017 |
| Pilot study of 99mTc-labeled ethylene dicysteine deoxyglucose SPECT-CT imaging in treatment response evaluation in patients with locally advanced head and neck cancer DT Ginat, C Westiin, RJ Brisson, C Chin, Y Pu, H Zhang, JA De Souza Cureus 9 (4), 2017 | 6 | 2017 |
